Summary & Overview
HCPCS J1951: Leuprolide Acetate Depot Injection, 0.25 mg
HCPCS Level II code J1951 designates the injection of leuprolide acetate for depot suspension (fensolvi), 0.25 mg. This injectable GnRH agonist dosage unit is used in treatments requiring sustained suppression of gonadal steroid production, making it relevant across oncology, reproductive endocrinology, and certain chronic hormone-dependent conditions. Nationally, outpatient administration of depot hormone therapies represents a notable portion of drug-administered services billed to major public and commercial payers.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for J1951, typical sites of service, and payer scope. The publication also summarizes benchmarks and coverage considerations, outlines common billing modifiers and service-line context, and highlights areas where policy updates or coding clarifications frequently occur.
This resource is intended to inform billing staff, practice managers, and policy analysts about the code’s clinical purpose, billing context, and what to examine in payer-specific reimbursement and coverage policies. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J1951 represents the injection of leuprolide acetate for depot suspension (fensolvi), 0.25 mg. This code denotes a single dosage unit of a depot formulation of leuprolide acetate used for therapeutic indications that require gonadotropin-releasing hormone (GnRH) agonist therapy.
Service Type: Drug administration – depot injectable medication
Typical Site of Service: Outpatient clinic, physician office, or ambulatory infusion center
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or adolescent receiving monthly depot leuprolide acetate (J1951, fensolvi 0.25 mg) for hormone‑sensitive conditions such as prostate cancer, endometriosis, uterine fibroids, or central precocious puberty management. The clinical workflow begins with a specialist consultation (urologist, gynecologist, pediatric endocrinologist) confirming indication and reviewing risks/benefits. Baseline labs (e.g., testosterone, estradiol, pregnancy test when applicable) and vital signs are obtained. The patient presents to an outpatient clinic, infusion center, or physician office at the scheduled interval. The medication is prepared per manufacturer instructions and administered as a subcutaneous or intramuscular depot injection by a licensed clinician. The clinician documents indication, lot number, dose, site of injection, and patient tolerance. Follow‑up visits include symptom assessment, monitoring for adverse effects (hot flashes, injection site reaction), and periodic lab monitoring to confirm therapeutic suppression. Typical sites of service include outpatient clinic, physician office, ambulatory infusion center, or hospital outpatient department depending on payer and clinical complexity.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier reported | Rare; not generally used—place only if required by specific payer. |